Plasma SARS-CoV-2 RNA Levels in Critically Ill COVID-19 Patients

Plasma SARS-CoV-2 RNA Levels in Critically Ill COVID-19 Patients (pRNA-COVID-ICU)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05115045

Acronym

pRNA-COVID-ICU

Enrollment

122

Registered

2021-11-10

Start date

2021-11-09

Completion date

2022-03-01

Last updated

2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ARDS Due to Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19 Pneumonia

Brief summary

Retrospective, observationnal study. Evaluation of the association between plasmatic SARS-CoV-2 RNA and day 60 mortality in ICU adult COVID-19 patients.

Interventions

DIAGNOSTIC_TESTplasmatic SARS-CoV-2 RNA quantification

plasmatic SARS-CoV-2 RNA was quantified by droplet digital PCR

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* age above 18 years * in ICU hospitalization * COVID-19 related pneumonia confirmed by PCR

Exclusion criteria

* plasmatic SARS-COV-2 RNA quantification not available * patient's refusal to participate

Design outcomes

Primary

Measure	Time frame	Description
Day 60 mortality	60 days	Association between plasmatic SARS-CoV-2 RNA level and mortality

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026